Loading clinical trials...

Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy | Clinical Trials | Clareo Health

COMPLETED

Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

Retrospective Study of Metastatic Left Colon and Rectal Cancer as Regard Treatment With Anti_EGFR Targeted Therapy

NCT06083974•Assiut University

Summary

Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage . New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti\_EGFR ,anti\_angiogenic and kinase inhibitors .

Detailed Description

Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti\_EGFR targeted therapy between left colon and rectal cancer

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. age above 18
•2. Both sex
•3. Performance status zero to one according to ECOG scale system
•4. Histo-pathologial diagnosis adenocarcinoma of left colon or rectum.
•5. Patients diagnosed with left colon and rectal cancer.
•6. Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC.
•7. Patients diagnosed with metastatic stage.
•8. K-RAS wild type.

Exclusion Criteria

•1. Second malignancy
•2. Histo-pathological types other than adenocarcinoma.
•3. Right colon cancer patients.
•4. Patients refused receiving anti\_EGFR targeted therapy.
•5. Patients with any abnormalities preventing to receive chemotherapy.
•6. Early stages of colorectal cancer.
•7. K-RAS mutant type.

Key Dates

Start Date

January 1, 2015

Primary Completion Date

December 30, 2022

Completion Date

December 30, 2022

Last Updated

October 16, 2023

Enrollment

100

ACTUAL participants

Conditions

Metastatic Colorectal Adenocarcinoma

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

NCT04511039

Advanced Malignant Solid NeoplasmClinical Stage III Gastroesophageal Junction Adenocarcinoma+27 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 16, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

Inclusion Criteria

Exclusion Criteria

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer